XmAb 13676Alternative Names: XmAb®13676
Latest Information Update: 25 Mar 2017
At a glance
- Originator Xencor
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action CD20 antigen modulators; CD3 antigen modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma